Remdesivir: green light from the European Commission

The United States have bought almost all of Remdesivir’s stocks, this promising drug against Covid-19. In Europe, the drug obtained the green light from the European Commission for a marketing.

The European Commission authorized on Friday “conditional marketing” of the antiviral remdesivir within the European Union. The European Medicines Agency gave its favorable opinion on June 25.

Like the American Medicines Agency (FDA) which authorized – as of May 1 – and “emergency“Remdesivir as part of the fight against the Sars-Cov-2 coronavirus on its territory. This antiviral drug initially developed to treat patients with Ebola is produced by the Gilead laboratory.

But for now, the United States has bought almost all the stocks of this promising drug, reports the British newspaper. The Guardian. For the next 3 months, no other country will be able to obtain this drug, which helps patients recover more quickly from the coronavirus. The United States has indeed bought purchased more than 500,000 doses of the drug, the entire production of Gilead for July and 90% of August and September.

Remdesivir: what is this medicine?

Remdesivir is a “viral RNA polymerase inhibitor”, a drug that interferes with the production of viral genetic material to prevent the virus from multiplying. It has shown wide activity in vitro against various viruses, including SARS-CoV-2. Remdesivir is also being tested for coronavirus treatment as part of the European Discovery clinical trial.

This antiviral drug developed in 2015 by Gilead laboratories (and named GS-5734 in medical language) has already proven its effectiveness against two viruses of the family of Coronaviridae : MERS-CoV et le SARS-CoV-1.

On April 29, 2020, after a large clinical trial conducted since February 2020 on 1063 patients in the United States, Europe and Asia, the American Institutes of Health (NIH) announced that “remdesivir has a clear, meaningful and positive effect in reducing recovery time“Covid-19 sufferers.

Remdesivir Reduces Patient Recovery Time and Mortality of Covid-19

In detail, the American researchers discovered that the recovery time of patients was shortened by 31% on average (or about 4 days) when treated with remdesivir. The death rate was about 3% lower.

The United States is paying a heavy price for the coronavirus epidemic that is raging on the planet today: it is unable to contain the epidemic. Lhe latest report shows 1,082 deaths in 24 hours, bringing the total to 112,833 deaths due to Covid-19.

Read also :

Subscribe to the Top Santé Newsletter and receive your light and delicious recipe booklet for free